Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 14

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 14
---
 the Exchange Shares based on their ownership in LipoVation. The Exchange Shares represented
approximately 40% of the issued and outstanding shares of the Company’s Common Stock immediately upon the closing of the Share
Exchange.

As a result of the Share Exchange, the Company
acquired the business of LipoVation, which became the primary business of the Company. Through LipoVation, the Company is dedicated to
developing novel nano-medicines to deliver advanced treatment solutions for diseases with limited or no effective medical options. Pursuant
to the license and research agreements with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (“Yissum”),
executed on November 24, 2022, as amended on October 25, 2023 (the “Yissum License Agreements”), LipoVation has exclusive
license rights to develop and market a novel technology related to Nano-Liposomal Particles (NLP)-based medicines including: (i) novel
formulation of a potent antibiotic which shows promise in combating several life-threatening antibiotic-resistant bacteria which currently
have no available treatment, (ii) potent adjunct to improve cancer treatment outcomes and (iii) novel immunization approach based on
Liposomal Protein-Loaded Technology (LPLT).

The Share Exchange and the Conversion are intended
to be treated as a tax-free reorganization under Section 368(a)(1)(F) of the Internal Revenue Code of 1986, as amended.

Prior to the closing of the Share Exchange, the
Company had been developing clinical decision-making support system (DMSS) in the field of mental health, including novel diagnostics
algorithm and treatment monitoring tools allowing for integrative care and evidence-based addiction treatment. After the closing
of the Share Exchange with LipoVation, the Company discontinued its prior activities and efforts with respect to the development and
activation of the DMSS and focused its business operations primarily on the acquired LipoVation’s business, specifically on developing
and marketing a range of novel NLP-based medicines to combat several life-threatening diseases which have no efficient treatment today.

Private Placement Offerings

Between December 2020 and August 2022, we conducted
a private placement offering (the “First Private Placement Offering”) of units of the Company’s securities, at the
price per unit of $0.80. Each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2) shares
of the